drugset / Trial / NCT07671924
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
Timeline
- Start
- 2026-06-22
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | 27 mg | Oral |
| Subject | Nalbuphine | Small molecule | 54 mg | Oral |
Indications
No indication recorded.